Gabapentin
Gabapentin
Neurontin, Gralise, Gabarone, Gabbies
Gabapentin is a depressant substance of the gabapentinoid class and a structural analogue of the neurotransmitter GABA1. Originally developed in the 1970s to treat epilepsy, it was first approved in the United States in 19932 and is now widely prescribed for neuropathic pain3, postherpetic neuralgia, and partial-onset seizures2. Its anxiolytic, sedative, and mildly euphoriant properties have led to recreational use1, though tolerance is known to develop rapidly.
Contents
Dosage & Duration
Dosage
Threshold~200 mg
Light200-600 mg
Moderate600-900 mg
Strong900-2400 mg
Heavy2400+ mg
Bioavailability
27-80% (dose-dependent)
Gabapentin exhibits dose-dependent oral bioavailability that decreases at higher amounts owing to saturation of intestinal amino acid transporters. Splitting a total dose into smaller portions taken at 30- to 45-minute intervals can improve absorption relative to a single large dose. Tolerance to the anxiolytic effects typically develops during continuous use and generally resolves within one to two weeks after discontinuation.
Duration
Onset30-120 minutes
Peak2-3 hours
After Effects1-6 hours
Total6-10 hours
Half-life
5-7 hours
Subjective Effects
Effects vary widely by individual, dose, and context.
Physical
Cognitive
Reagent Testing
Loading reagent data
Expected colorimetric results are being prepared.
Pharmacology
Pharmacodynamics
Gabapentin primarily acts by binding to the α2δ-1 subunit of voltage-gated calcium channels.4 Rather than directly blocking the channel pore, it disrupts the trafficking of calcium channel complexes to the presynaptic membrane, reducing excitatory neurotransmitter release.4 Gabapentin also competitively inhibits branched-chain aminotransferase (BCAT-1), slowing glutamate synthesis,5 and modulates glutamate decarboxylase, with neuroimaging studies showing it increases cerebral GABA concentrations by up to 79% from baseline. Despite its structural similarity to GABA, it does not convert to GABA in vivo and does not function as a GABA receptor agonist, though antagonist activity at GABA-B receptor subunits has been separately reported. Secondary targets include KCNQ3 and KCNQ5 potassium channels6 and the adenosine A1 receptor, though the clinical relevance of these interactions remains unclear.
Pharmacokinetics
Gabapentin undergoes virtually no hepatic metabolism, with less than 1% of an administered dose recovered as metabolites.7 It is eliminated almost entirely as unchanged drug in the urine, with clearance directly proportional to creatinine clearance.7 Absorption occurs through a saturable amino acid transporter (LAT) in the intestines, resulting in dose-dependent oral bioavailability that decreases substantially at higher doses (approximately 80% at 100 mg per dose down to 27% at 1600 mg per dose).7 Gabapentin crosses the blood-brain barrier via the LAT1 transporter,8 achieving cerebrospinal fluid concentrations of approximately 9-14% of plasma levels. Plasma protein binding is minimal (less than 3%).7
Metabolitesnone documented yet
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Tolerance
Full Tolerance
Tolerance to anxiolytic and euphoric effects can build rapidly with repeated dosing, sometimes after several days in a row. Reported recreational benefits may fade quickly, with repeat doses producing much smaller returns even during the same session.
Baseline Reset
Tolerance returns to baseline within 7-14 days after cessation of use.
Harm Potential
Addiction & Dependence
Psychological
LowGabapentin is not considered psychologically addictive and demonstrates limited to no rewarding effects in human and animal experiments.9 Compulsive drug-seeking behavior and strong cravings are generally not observed, unlike with opioids, alcohol, or benzodiazepines. However, misuse does occur, particularly among individuals with a history of opioid or sedative abuse who may use it to boost opioid effects or manage withdrawal symptoms.109
Physical
ModeratePhysical dependence develops with chronic use, with withdrawal symptoms typically emerging 1-2 days after abrupt cessation11 and potentially lasting up to 45 days. Withdrawal symptoms are similar to, though generally less intense than, benzodiazepine withdrawal11 and include agitation, confusion, disorientation, gastrointestinal complaints, sweating, and less commonly tremor, tachycardia, hypertension, and insomnia.1213 Withdrawal seizures have been reported following chronic use without periodic breaks.12 Gradual tapering is recommended.11
Toxicity
Cardiovascular
Prolonged gabapentinoid use exceeding one year has been associated with increased risk of cardiovascular events and thrombotic events including deep venous thrombosis and pulmonary thromboembolism; thrombotic risk may emerge as early as three months of use.14
Immunological
Rare cases of drug reaction with eosinophilia and systemic symptoms (DRESS), a potentially fatal multi-organ hypersensitivity reaction, have been reported with gabapentin use.12
Renal
Gabapentin may accumulate in patients with renal impairment, potentially leading to increased toxicity due to diminished clearance rather than direct nephrotoxicity; careful dosing is required in those with kidney problems.12
Reproductive
Sexual dysfunction including loss of libido, anorgasmia, and erectile dysfunction may occur in some patients during gabapentin use.12
Respiratory
Serious breathing suppression may occur when gabapentin is taken by individuals with underlying lung conditions such as COPD, independent of combination with other substances.15
Psychosis Risk
Psychiatric and behavioral adverse effects including hallucinations and psychosis can occur but are rare, primarily affecting pediatric populations and individuals with preexisting psychiatric conditions.12 Milder neuropsychiatric symptoms including confusion, depression, mood instability, aggression, agitation, and behavioral disturbances may occur in up to 29% of gabapentin users, though most reactions are mild to moderate and dose-dependent. The FDA has issued warnings regarding increased risk of suicidal thoughts and behaviors;12 some studies suggest approximately 40% increased risk of suicide or suicide attempt compared to other anticonvulsants, particularly in patients with bipolar disorder or epilepsy,16 though conflicting data exists with some studies showing reduced suicide rates in certain populations.17
Seizure Risk
Gabapentin is an anticonvulsant that reduces seizure activity during use. However, withdrawal seizures may occur in some cases following chronic or semi-chronic use when the drug is discontinued abruptly, particularly in the absence of periodic breaks during repeated consecutive use.12 Gradual tapering is recommended to minimize withdrawal seizure risk.
History & Culture
Discovery and Development
Gabapentin was conceived and synthesized at Goedecke AG, a Parke-Davis subsidiary located in Freiburg, Germany.18 The compound was designed as a structural analog of gamma-aminobutyric acid (GABA) with enhanced capacity to penetrate the blood-brain…
Legality
By Country
United StatesPrescription onlyRx only
Gabapentin is a prescription drug in the United States. Its current FDA label states that it is not a controlled substance, and it is not listed in the federal controlled-substance schedules in 21 CFR Part 1308. State controlled-substance scheduling and prescription-monitoring requirements vary by jurisdiction.
By state
Across the 50 states, D.C., and the permanent territories, most jurisdictions treat gabapentin consistently with federal prescription-drug law, while some jurisdictions schedule it as a controlled substance or impose prescription-monitoring requirements beyond the federal baseline.
AlabamaRestrictedSchedule V controlled substance
ArkansasRestrictedSchedule V controlled substance
ConnecticutRestrictedPMP-reportable
DelawareNot scheduledNot listed in Schedules I–V
District of ColumbiaRestrictedPDMP-reportable drug of concern
IllinoisRestrictedPMP drug of interest
IndianaRestrictedINSPECT-reportable
KansasRestrictedK-TRACS drug of concern
KentuckyRestrictedSchedule V controlled substance
MassachusettsRestrictedSchedule VI / PMP
MinnesotaRestrictedPMP-reportable
MississippiRestrictedPMP drug of concern
MontanaRestrictedSchedule V
New JerseyRestrictedPMP-reportable
New MexicoRestrictedDrug of concern
North CarolinaRestrictedCSRS-reportable drug
North DakotaRestrictedSchedule V
OhioRestrictedOARRS review
OregonRestrictedPMP-reportable
TennesseeRestrictedSchedule V controlled substance
UtahRestrictedSchedule V
VirginiaRestrictedSchedule V
West VirginiaRestrictedSchedule V controlled substance
WisconsinRestrictedMonitored prescription drug
WyomingRestrictedPMP-reportable
AustriaPrescription onlyRezept- und apothekenpflichtig
BASG Fachinformation for Gabapentin 1A Pharma 300 mg/400 mg Hartkapseln30
Gabapentin 1A Pharma 300 mg and 400 mg hard capsules are authorised medicinal products in Austria. The current BASG product information identifies the 300 mg product as authorisation number 1-27113 and states that both strengths are prescription- and pharmacy-only.
BrazilPrescription onlyLista C1
Gabapentin is listed as Gabapentina in Lista C1 of ANVISA's current consolidated Portaria SVS/MS no. 344/1998. Lista C1 substances require a Receita de Controle Especial in two copies; dispensing is restricted to pharmacies or drugstores and requires that prescription, with the first copy retained by the dispensing establishment.
Czech RepublicPrescription onlyR — na lékařský předpis
SÚKL Přehled léčiv product record for GABAGAMMA 100MG CPS DUR 100 (SÚKL code 0126157)36
The current SÚKL Přehled léčiv record for GABAGAMMA 100MG CPS DUR 100 identifies GABAPENTIN as its active substance and gives its dispensing code as R, meaning a medicinal product subject to medical prescription. The same official record identifies the product as holding a valid marketing authorisation; this finding is limited to the dispensing classification recorded for that authorised gabapentin medicine.
FrancePrescription onlyOrdonnance
Base de données publique des médicaments38
Gabapentin is supplied only on prescription in France. The public medicines database records the prescription-only supply condition for authorised gabapentin products.
IndiaPrescription onlySchedule H
Gabapentin is listed in Schedule H to India's Drugs Rules, 1945. Retail sale requires a prescription from a Registered Medical Practitioner.
IsraelPrescription onlyחייב במרשם רופא
Gabapentin is a prescription medicine in Israel. The Ministry of Health Drug Registry marks registered Gabapentin Teva and Neurontin products as requiring a doctor's prescription.
JapanPrescription only処方箋医薬品
MHLW Notice No. 24 of 2005 under Article 49(1) of the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices4849
Gabapentin is a prescription medicine in Japan. Ministry of Health, Labour and Welfare Notice No. 24 of 2005 lists gabapentin among the medicines designated under Article 49(1) of the pharmaceuticals law. PMDA's current approved Gabapen Tablets package insert classifies the product as 処方箋医薬品 and directs that it be used on the prescription of a physician or other practitioner.
New ZealandPrescription onlyPrescription medicine
Medicines Act 1981; Medsafe medicine information51
Gabapentin is a prescription medicine in New Zealand. Medsafe's current medicine information identifies gabapentin as prescription medicine.
RussiaPrescription onlyПо рецепту
State Register of Medicines record for Gabapentin-LEXVM (ЛП-№(015722)-(РГ-RU))53
Gabapentin is registered in Russia as a prescription medicine. The State Register of Medicines records Gabapentin-LEXVM capsules as dispensed by prescription.
South KoreaPrescription only전문의약품
MFDS Integrated Drug Information System product record55
Gabapentin is classified as a prescription drug (전문의약품) in South Korea. The Ministry of Food and Drug Safety's current product record for Ganutin Capsule 300 mg identifies gabapentin as its active ingredient and classifies the product as a prescription drug.
SwedenPrescription onlyReceptbelagd
Läkemedelsverket Läkemedelsfakta57
Gabapentin is a prescription medicine in Sweden. The Swedish Medical Products Agency's medicine record marks authorised gabapentin products as prescription-only.
ThailandRestrictedยาอันตราย
Notification of the Ministry of Public Health Re: Dangerous Drugs (as amended through No. 36), issued under the Drug Act B.E. 251062636465
Gabapentin is classified in Thailand as a dangerous drug (ยาอันตราย), rather than as an unrestricted over-the-counter medicine. The current Dangerous Drugs notification covers antiepileptic and anticonvulsant drugs other than specially controlled drugs or psychotropic substances, and the Thai FDA's current product record specifically classifies a gabapentin product in that category. Its retail supply is therefore subject to the Drug Act's licensed dangerous-drug sale regime rather than the licence limited to ready-packed drugs that are not dangerous drugs or specially controlled drugs.
United Arab EmiratesRestrictedCD
MOHAP Controlled and Semi-Controlled Medicines List67
Gabapentin is listed as a controlled drug in the United Arab Emirates. Its supply is therefore subject to the Ministry of Health and Prevention's controlled-medicines requirements.
AustraliaPrescription onlySchedule 4
Regulated as a prescription medicine. Available through licensed healthcare providers and pharmacies with a valid prescription.29
BelgiumPrescription onlyPrescription
FAGG/AFMPS authorised product information31
Gabapentin is supplied on medical prescription in Belgium. The federal medicines agency's authorised product leaflet states that the medicine is available on prescription.
CanadaPrescription only
Food and Drug Regulations, Prescription Drug List34
Available as a prescription medication with multiple branded and generic formulations approved for medical use.35
DenmarkPrescription onlyReceptpligtigt
Danish Medicines Agency prescription-medicines list37
Gabapentin is a prescription medicine in Denmark. The Danish Medicines Agency lists gabapentin among prescription medicines with general reimbursement.
GermanyPrescription onlyAnlage 1
Arzneimittelverschreibungsverordnung, Anlage 139
Listed in Anlage 1 of the Arzneimittelverschreibungsverordnung (AMVV), requiring a prescription for dispensing.39 Regulated as a prescription-only medicine rather than a controlled narcotic substance.
IrelandPrescription onlyPrescription (B)
Medicinal Products (Prescription and Control of Supply) Regulations 2003 (S.I. No. 540/2003), regulation 5 and First Schedule; HPRA authorised-medicine record for Neurontin 400 mg hard capsules4243
Gabapentin is subject to prescription control in Ireland. The First Schedule to the Medicinal Products (Prescription and Control of Supply) Regulations 2003 lists gabapentin in Part B, and regulation 5 provides that a medicinal product containing a listed substance may not be supplied except in accordance with a prescription, subject to the stated exceptions. The current HPRA record for authorised Neurontin 400 mg hard capsules identifies gabapentin as the active substance and gives its legal supply status as a product subject to prescription which may be renewed (B).
ItalyPrescription onlyRNR — prescrizione medica da rinnovare
AIFA's current Banca Dati Farmaci record identifies Gabapentin EG 300 mg hard capsules as containing gabapentin and records the supply class RNR, described as medicines subject to medical prescription to be renewed. The listed package is authorised and marketed, supporting prescription-only supply for this authorised gabapentin medicine in Italy.
NetherlandsPrescription onlyUR
Geneesmiddeleninformatiebank authorised-medicine record50
Gabapentin is a prescription-only medicine in the Netherlands. The official medicines-information database classifies the authorised product with the UR supply status.
NorwayPrescription onlyReseptgruppe C
Legemiddelsøk medicine register52
Gabapentin is prescription-only in Norway. The official medicine register marks the authorised product as prescription-required and places it in prescription group C.
SingaporePrescription onlyPRESCRIPTION ONLY MEDICINES
Health Sciences Authority National Drug Formulary product record: ALPENTIN CAPSULE 100MG (SIN16698P)54
Singapore’s Health Sciences Authority National Drug Formulary lists ALPENTIN CAPSULE 100MG with gabapentin 100 mg as its active ingredient and classifies that registered product as a prescription-only medicine. This finding concerns the currently listed registered gabapentin product and does not assert a separate controlled-drug classification.
SpainPrescription only
AEMPS CIMA medicines-register records for Gabapentina Almus products56
AEMPS CIMA's current medicines-register response identifies Gabapentina Almus 300 mg and 400 mg hard capsules and 600 mg and 800 mg film-coated tablets as gabapentin products. Each record gives the dispensing classification ‘Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración’ and marks the product as requiring a prescription (receta: true); all four records are marked as marketed (comerc: true).
SwitzerlandPrescription onlyB
Classified as a Category B pharmaceutical under Swiss pharmaceutical law, requiring a medical prescription for dispensing.61
UkrainePrescription onlyза рецептом
State Register of Medicinal Products of Ukraine66
Gabapentin 400 mg capsules are registered in Ukraine in the State Register of Medicinal Products. The register records their dispensing condition as "за рецептом" (by prescription), so supply is prescription-only.
References
Source Pages
Citations
- Smith RV, Havens JR, & Walsh SL. (July 2016). Gabapentin misuse, abuse and diversion: a systematic review. Addiction, 111(7), 1160–1174. https://doi.org/10.1111/add.1332412
- (2025). NEURONTIN (gabapentin) Prescribing Information. DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=97935fd9-1d4a-43b6-a5d9-de994591187b&type=display12345
- (n.d.). Gabapentin — StatPearls. StatPearls Publishing / NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK493228/12
- Hendrich J, Tran Van Minh A, Heblich F, Nieto-Rostro M, Watschinger K, Striessnig J, Wratten J, Davies A, & Dolphin AC. (2008). Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin. Proceedings of the National Academy of Sciences USA, 105(9), 3628-3633. https://doi.org/10.1073/pnas.070893010512
- Hutson SM, Berkich D, Drown P, Xu B, Aschner M, & LaNoue KF. (1998). Role of branched-chain aminotransferase isoenzymes and gabapentin in neurotransmitter metabolism. Journal of Neurochemistry, 71(2), 863-874. https://pubmed.ncbi.nlm.nih.gov/9681479/1
- (October 2018). Gabapentin Is a Potent Activator of KCNQ3 and KCNQ5 Potassium Channels. Molecular Pharmacology, 94(4), 1155–1163. https://doi.org/10.1124/mol.118.1129531
- (n.d.). Neurontin (gabapentin) Prescribing Information. Pfizer Inc.. https://labeling.pfizer.com/showlabeling.aspx?id=6301234
- (June 2013). Transport of gabapentin by LAT1 (SLC7A5). Biochemical Pharmacology, 85(11), 1672–1683. https://doi.org/10.1016/j.bcp.2013.03.0221
- (June 2014). Misuse and abuse of pregabalin and gabapentin: cause for concern?. CNS Drugs, 28(6), 491–496. https://doi.org/10.1007/s40263-014-0164-412
- (March 2017). Abuse and Misuse of Pregabalin and Gabapentin. Drugs, 77(4), 403–426. https://doi.org/10.1007/s40265-017-0700-x1
- (June 2005). Gabapentin withdrawal syndrome in the presence of a taper. Bipolar Disorders, 7(3), 302–4. https://doi.org/10.1111/j.1399-5618.2005.00200.x123
- (2017). NEURONTIN (gabapentin) Prescribing Information. Pfizer Inc.. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=798575b9-ddfa-4915-9574-626abbaf025f1234567891011
- (March 2016). Gabapentin: Abuse, Dependence, and Withdrawal. The Annals of Pharmacotherapy, 50(3), 229–233. https://doi.org/10.1177/10600280156208001
- (Apr 2025). Cardiovascular safety of gabapentinoids gabapentin & pregabalin: A systematic review.. Indian J Med Res, 161(4), 363–374. https://doi.org/10.25259/ijmr_1990_202412
- (January 2024). Gabapentinoids and Risk for Severe Exacerbation in Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study. Annals of Internal Medicine, 177(Online ahead of print), 144–154. https://doi.org/10.7326/m23-084912
- (April 2010). Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA, 303(14), 1401–1409. https://doi.org/10.1001/jama.2010.4101
- (Oct 2010). Gabapentin and suicide attempts. Pharmacoepidemiology and Drug Safety, 19(12). https://doi.org/10.1002/pds.20361
- (n.d.). Gabapentin — Chemistry World Podcast. Chemistry World (Royal Society of Chemistry). https://www.chemistryworld.com/podcasts/gabapentin/1017577.article123
- Panebianco M, Al-Bachari S, Hutton JL, & Marson AG. (2021). Gabapentin add-on treatment for drug-resistant focal epilepsy. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd001415.pub41
- Peckham AM, Evoy KE, Ochs L, & Covvey JR. (2018). Gabapentin for Off-Label Use: Evidence-Based or Cause for Concern?. Substance Abuse: Research and Treatment. https://doi.org/10.1177/117822181880131112
- Depomed Inc.. (2011-01-29). Depomed Announces US Food and Drug Administration Approval of GRALISE (gabapentin) Once-Daily Tablets for Treatment of Post-Herpetic Neuralgia. GlobeNewsWire. https://www.globenewswire.com/news-release/2011/01/29/438783/12812/en/Depomed-Announces-US-Food-and-Drug-Administration-Approval-of-GRALISE-TM-gabapentin-Once-Daily-Tablets-for-Treatment-of-Post-Herpetic-Neuralgia.html1
- (2025). The Top 300 of 2023. ClinCalc DrugStats. https://clincalc.com/DrugStats/Top300Drugs.aspx1
- (2004). Warner-Lambert to Pay $430 Million to Resolve Criminal & Civil Health Care Liability Relating to Off-Label Promotion. U.S. Department of Justice. https://www.justice.gov/archive/opa/pr/2004/May/04_civ_322.htm1234
- (February 2012). Double-blind placebo-controlled evaluation of the PROMETA™ protocol for methamphetamine dependence. Addiction, 107(2), 361–369. https://doi.org/10.1111/j.1360-0443.2011.03619.x12
- Buttram ME, Kurtz SP, Dart RC, & Margolin ZR. (2017). Law enforcement-derived data on gabapentin diversion and misuse, 2002-2015: diversion rates and qualitative research findings. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.42301
- (June 2019). Trending gabapentin exposures in Kentucky after legislation requiring the use of the state prescription drug monitoring program for all opioid prescriptions. Clinical Toxicology, 57(6), 398–403. https://doi.org/10.1080/15563650.2018.15385181
- (n.d.). Poisons Standard (SUSMP). tga.gov.au. https://www.tga.gov.au/resources/publication/publications/poisons-standard-susmp1
- (n.d.). Scheduling basics of medicines and chemicals in Australia. tga.gov.au. https://www.tga.gov.au/products/regulations-all-products/ingredients-and-scheduling-medicines-and-chemicals/scheduling-national-classification-system/scheduling-basics-medicines-and-chemicals-australia1
- (n.d.). Gabapentin (Aspen) – Healthdirect Australia. Healthdirect Australia / Therapeutic Goods Administration. https://www.healthdirect.gov.au/medicines/brand/amt,112611000036104/gabapentin-aspen1
- (n.d.). BASG Fachinformation for Gabapentin 1A Pharma 300 mg/400 mg Hartkapseln. medikamente.basg.gv.at. https://medikamente.basg.gv.at/documents/1-27114__DOTC_FACH_INFO.pdf1
- (n.d.). Portaria SVS/MS no. 344/1998, current consolidated text, Lista C1 and arts. 52–53. anvisalegis.datalegis.net. https://anvisalegis.datalegis.net/action/ActionDatalegis.php?acao=abrirTextoAto&tipo=POR&numeroAto=00000344&seqAto=000&valorAno=1998&orgao=SVS/MS&codTipo=&desItem=&desItemFim=&cod_menu=1696&cod_modulo=134&pesquisa=true1
- (n.d.). Portaria SVS/MS no. 344/1998, current consolidated text, Lista C1 and arts. 52–53. gov.br. https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/controlados/lista-substancias1
- (n.d.). Health Canada Drug Product Database: GABAPENTIN (DIN 02431289). health-products.canada.ca. https://health-products.canada.ca/dpd-bdpp/info?code=91570&lang=eng1
- (n.d.). AURO-GABAPENTIN – Drug Product Database, Health Canada. Health Canada. https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=806611
- (n.d.). SÚKL Přehled léčiv product record for GABAGAMMA 100MG CPS DUR 100 (SÚKL code 0126157). prehledy.sukl.cz. https://prehledy.sukl.cz/prehledy/v1/dlp/01261571
- (n.d.). Danish Medicines Agency prescription-medicines list. laegemiddelstyrelsen.dk. https://laegemiddelstyrelsen.dk/ftp-upload/recept_lm_gen_uklaus_til.pdf1
- (n.d.). Base de données publique des médicaments. base-donnees-publique.medicaments.gouv.fr. https://base-donnees-publique.medicaments.gouv.fr/medicament/64552794/extrait1
- (n.d.). Anlage 1 – Arzneimittelverschreibungsverordnung (AMVV). Bundesministerium der Justiz / gesetze-im-internet.de. https://www.gesetze-im-internet.de/amvv/anlage_1.html12
- (n.d.). Central Drugs Standard Control Organization: Drugs Rules, 1945 (current consolidated text dated 1 July 2024). cdsco.gov.in. https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2022/drug_rules/Drugs%20Rules%201945_2024%2009.pdf1
- (n.d.). Central Drugs Standard Control Organization: Drugs Rules, 1945 official publication page. cdsco.gov.in. https://cdsco.gov.in/opencms/opencms/en/Acts-and-rules/Drugs-Rules/1
- (n.d.). Israel Ministry of Health Drug Registry. israeldrugs.health.gov.il. https://israeldrugs.health.gov.il/#!/medDetails/119%2046%2029956%20001
- (n.d.). Israel Ministry of Health Drug Registry. israeldrugs.health.gov.il. https://israeldrugs.health.gov.il/local/he.js1
- (n.d.). AIFA Banca Dati Farmaci record for Gabapentin EG 300 mg capsule rigide. api.aifa.gov.it. https://api.aifa.gov.it/aifa-bdf-eif-be/1.0.0/formadosaggio/0000036713?lang=it1
- (n.d.). AIFA Banca Dati Farmaci record for Gabapentin EG 300 mg capsule rigide. api.aifa.gov.it. https://api.aifa.gov.it/aifa-bdf-eif-be/1.0.0/formadosaggio/ricerca?query=gabapentin&page=01
- (n.d.). Ministry of Health, Labour and Welfare Notice No. 24 of 2005: medicines designated under Article 49(1). mhlw.go.jp. https://www.mhlw.go.jp/web/t_doc?dataId=81aa6750&dataType=01
- (n.d.). PMDA approved package insert: Gabapen Tablets 200 mg, 300 mg and 400 mg. pmda.go.jp. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/670109_1139007F1022_3_031
- (n.d.). Medicines Act 1981; Medsafe medicine information. medsafe.govt.nz. https://www.medsafe.govt.nz/committees/marc/reports/184-3.2.1Gabapentin.pdf1
- (n.d.). Legemiddelsøk medicine register. legemiddelsok.no. https://www.legemiddelsok.no/sider/Legemiddelvisning.aspx?f=&pakningId=a1716a45-c1ba-43c6-842c-d50766b41c6f&pane=0&searchquery=Gabapentin1
- (n.d.). State Register of Medicines: Gabapentin-LEXVM registration record. grls.rosminzdrav.ru. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=70d28adf-1d17-4307-91dc-d346ebceb3901
- (n.d.). Ministry of Food and Drug Safety Integrated Drug Information System: Ganutin Capsule 300 mg (gabapentin). nedrug.mfds.go.kr. https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=2020013361
- (n.d.). AEMPS CIMA medicines-register records for Gabapentina Almus products. cima.aemps.es. https://cima.aemps.es/cima/rest/medicamentos?nombre=Gabapentina%20Almus1
- (n.d.). Läkemedelsverket Läkemedelsfakta. lakemedelsverket.se. https://www.lakemedelsverket.se/sv/sok-lakemedelsfakta/lakemedel/20181102000069/gabapentin-strides-400-mg-kapsel-hard1
- (n.d.). Arzneimittelverordnung (VAM), Art. 42; Swissmedic Journal 02/2025. swissmedic.ch. https://www.swissmedic.ch/dam/swissmedic/it/dokumente/stab/journal/swissmedic-journal02-2025.pdf.download.pdf/Swissmedic%20Journal%2002-2025_web.pdf1
- (n.d.). Arzneimittelverordnung (VAM), Art. 42; Swissmedic Journal 02/2025. fedlex.admin.ch. https://www.fedlex.admin.ch/eli/cc/2018/588/de1
- (n.d.). Arzneimittelverordnung (VAM), Art. 42; Swissmedic Journal 02/2025. fedlex.admin.ch. https://www.fedlex.admin.ch/eli/cc/2011/363/de1
- (n.d.). Gabapentin Sandoz eco Kaps 100 mg – Compendium.ch. HCI Solutions / Swissmedic-authorized compendium. https://compendium.ch/product/1155007-gabapentin-sandoz-eco-kaps-100-mg/mpub1
- (n.d.). Notification of the Ministry of Public Health Re: Dangerous Drugs (as amended through No. 36), issued under the Drug Act B.E. 2510. drug.fda.moph.go.th. https://drug.fda.moph.go.th/announcement-ministry/dangerous-drugs-11
- (n.d.). Notification of the Ministry of Public Health Re: Dangerous Drugs (as amended through No. 36), issued under the Drug Act B.E. 2510. pertento.fda.moph.go.th. http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug.aspx?drgtpcd=5&Newcode_U=U1DR1A1052630008311C&pvncd=10&rgtno=6300083&rgttpcd=1A1
- (n.d.). Notification of the Ministry of Public Health Re: Dangerous Drugs (as amended through No. 36), issued under the Drug Act B.E. 2510. drug.fda.moph.go.th. https://drug.fda.moph.go.th/drug-act1
- (n.d.). Notification of the Ministry of Public Health Re: Dangerous Drugs (as amended through No. 36), issued under the Drug Act B.E. 2510. en.fda.moph.go.th. https://en.fda.moph.go.th/media.php?id=504124621688283136&name=2.+Drug+Acts+B.E.2510+and+amendment+2001.pdf1
- (n.d.). State Register of Medicinal Products of Ukraine — ГАБАПЕНТИН, UA/21261/01/03. drlz.com.ua. http://www.drlz.com.ua/ibp/ddsite.nsf/all/shlz1?opendocument&stype=659A7E5F6C03DBBEC2258DED002DC41B1
- (n.d.). MOHAP Controlled and Semi-Controlled Medicines List. mohap.gov.ae. https://mohap.gov.ae/documents/20117/1212145/Controlled%2Band%2Bsemi-controlled%2Bmedicines%2Blist%2B-%2B331%2BKB.pdf/b50bbe06-b8c8-0635-60ae-dd9fe1e43b15?t=17391551410121
- (n.d.). The Misuse of Drugs Act 1971 (Amendment) Order 2018. legislation.gov.uk. https://www.legislation.gov.uk/uksi/2018/1356/article/2/made1
- (n.d.). The Misuse of Drugs Regulations 2001, Schedule 3. legislation.gov.uk. https://www.legislation.gov.uk/uksi/2001/3998/schedule/31
- (n.d.). The Misuse of Drugs Act 1971 (Amendment) Order 2018 (S.I. 2018/1356). UK Parliament / legislation.gov.uk. https://www.legislation.gov.uk/uksi/2018/1356/made1
- (n.d.). Federal Food, Drug, and Cosmetic Act § 503(b), 21 U.S.C. § 353(b); 21 CFR Part 1308. uscode.house.gov. https://uscode.house.gov/view.xhtml?edition=prelim&num=0&req=granuleid%3AUSC-prelim-title21-section3531
- (n.d.). Federal Food, Drug, and Cosmetic Act § 503(b), 21 U.S.C. § 353(b); 21 CFR Part 1308. ecfr.gov. https://www.ecfr.gov/current/title-21/chapter-II/part-13081
- (n.d.). Federal Food, Drug, and Cosmetic Act § 503(b), 21 U.S.C. § 353(b); 21 CFR Part 1308. dailymed.nlm.nih.gov. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=07aa1bcc-df05-44fa-92d4-63894e0e6cd61
- (n.d.). Alabama State Board of Health, Controlled Substances List, Schedule V. adfs.alabama.gov. https://adfs.alabama.gov/Content/pdfs/drug-chemistry/Controlled%20Substance%20List%202022.pdf1
- (n.d.). Arkansas Department of Health, List of Controlled Substances, Schedule V. healthy.arkansas.gov. https://healthy.arkansas.gov/wp-content/uploads/Controlled-Substances-List-7.3.25.pdf1
- (n.d.). Arkansas Department of Health, List of Controlled Substances, Schedule V. healthy.arkansas.gov. https://healthy.arkansas.gov/programs-services/prevention-healthy-living/pharmacy-services-drug-control/controlled-substances/1
- (n.d.). Connecticut Department of Consumer Protection CPMRS requirement, effective January 1, 2021. portal.ct.gov. https://portal.ct.gov/dcp/knowledge-base/articles/drug-control/pmp/gabapentin-and-naloxone-added-to-cpmrs1
- (n.d.). Connecticut Department of Consumer Protection CPMRS requirement, effective January 1, 2021. eregulations.ct.gov. https://eregulations.ct.gov/eRegsPortal/Browse/getDocument?guid=%7B70DF796A-0100-CB84-9777-C1FC46DBFDD4%7D1
- (n.d.). Delaware Uniform Controlled Substances Act, 16 Del. C. §§ 4712, 4714–4722. delcode.delaware.gov. https://delcode.delaware.gov/title16/c047/sc02/index.html1
- (n.d.). D.C. Code §§ 48-853.01, 48-853.03; District of Columbia PDMP Data Submission Dispenser Guide. dchealth.dc.gov. https://dchealth.dc.gov/sites/default/files/dc/sites/doh/page_content/attachments/Washington-DC-Data-Submission-Dispenser-Guide-v2.pdf1
- (n.d.). D.C. Code §§ 48-853.01, 48-853.03; District of Columbia PDMP Data Submission Dispenser Guide. code.dccouncil.gov. https://code.dccouncil.gov/us/dc/council/code/sections/48-853.031
- (n.d.). D.C. Code §§ 48-853.01, 48-853.03; District of Columbia PDMP Data Submission Dispenser Guide. code.dccouncil.gov. https://code.dccouncil.gov/us/dc/council/code/sections/48-853.011
- (n.d.). Illinois Prescription Monitoring Program, current Drugs of Interest list. ilpmp.org. https://www.ilpmp.org/pharmacy-registration-reporting1
- (n.d.). Indiana Code, title 25, article 26, chapter 24. iga.in.gov. https://iga.in.gov/laws/2025/ic/titles/25#25-26-241
- (n.d.). Indiana Professional Licensing Agency, INSPECT. in.gov. https://www.in.gov/pla/inspect/1
- (n.d.). Indiana Professional Licensing Agency, INSPECT FAQs. in.gov. https://www.in.gov/pla/inspect/faqs/1
- (n.d.). Kansas Board of Pharmacy—K-TRACS. pharmacy.ks.gov. https://www.pharmacy.ks.gov/?navid=2021
- (n.d.). Kansas Board of Pharmacy—Reporting to K-TRACS. ktracs.ks.gov. https://www.ktracs.ks.gov/pharmacists/reporting-to-k-tracs1
- (n.d.). 902 KAR 55:015, Schedules of controlled substances. apps.legislature.ky.gov. https://apps.legislature.ky.gov/law/kar/downloads/docs/16424/document.markup.pdf1
- (n.d.). M.G.L. c. 94C, § 3. malegislature.gov. https://malegislature.gov/Laws/GeneralLaws/PartI/TitleXV/Chapter94C/Section31
- (n.d.). Massachusetts Department of Public Health—Pharmacy reporting and data submission. mass.gov. https://www.mass.gov/info-details/pharmacy-reporting-and-data-submission1
- (n.d.). Minnesota Statutes § 152.126. revisor.mn.gov. https://www.revisor.mn.gov/statutes/cite/152.126/pdf1
- (n.d.). Minnesota Board of Pharmacy—Drugs required to be reported. mn.gov. https://mn.gov/boards/pharmacy-pmp/submissions/reporting/drugs/index.jsp1
- (n.d.). Mississippi Board of Pharmacy, The Script, April 2021. mbp.ms.gov. https://www.mbp.ms.gov/sites/default/files/inline-images/The%20Script%20VOL%208%20April%202021.pdf1
- (n.d.). Mississippi PMP Data Submission Guide. pmp.mbp.ms.gov. https://pmp.mbp.ms.gov/sites/default/files/pmp/forms-documents/MS-PMP-Data-Submission-Dispenser-Guide_v3.0.pdf1
- (n.d.). Montana Code Annotated § 50-32-232. mca.legmt.gov. https://mca.legmt.gov/bills/mca/title_0500/chapter_0320/part_0020/section_0320/0500-0320-0020-0320.html1
- (n.d.). Montana Board of Pharmacy gabapentin fact sheet. boards.bsd.dli.mt.gov. https://boards.bsd.dli.mt.gov/_docs/pha/PHA-Gabapentin-Fact-Sheet-Prescribers-Patients-09-2025.pdf1
- (n.d.). N.J.A.C. 13:45A-35.3(a). njconsumeraffairs.gov. https://www.njconsumeraffairs.gov/Adoptions/dirado_06032019.pdf1
- (n.d.). N.J.A.C. 13:45A-35.3(a). law.cornell.edu. https://www.law.cornell.edu/regulations/new-jersey/N-J-A-C-13-45A-35-31
- (n.d.). 16.19.29.7(F) NMAC; 16.19.29.8 NMAC. srca.nm.gov. https://www.srca.nm.gov/parts/title16/16.019.0029.html1
- (n.d.). 16.19.29.7(F) NMAC; 16.19.29.8 NMAC. rld.nm.gov. https://www.rld.nm.gov/wp-content/uploads/2022/10/Gabapentin-notification.pdf1
- (n.d.). N.C. Gen. Stat. § 90-113.73(b), as amended by Session Law 2023-65, Part XI, § 11.1. ncdhhs.gov. https://www.ncdhhs.gov/gabapentin-faq-dispensers-final-v3/open1
- (n.d.). N.C. Gen. Stat. § 90-113.73(b), as amended by Session Law 2023-65, Part XI, § 11.1. ncdhhs.gov. https://www.ncdhhs.gov/divisions/mental-health-developmental-disabilities-and-substance-use-services/north-carolina-drug-control-unit/north-carolina-controlled-substances-act/nc-controlled-substances-reporting-system-legal-updates1
- (n.d.). N.D. Cent. Code § 19-03.1-13(5)(g). ndlegis.gov. https://ndlegis.gov/cencode/t19c03-1.pdf1
- (n.d.). Ohio Administrative Code 4729:5-5-08. codes.ohio.gov. https://codes.ohio.gov/ohio-administrative-code/rule-4729:5-5-081
- (n.d.). Ohio Administrative Code 4729:8-2-02. codes.ohio.gov. https://codes.ohio.gov/ohio-administrative-code/rule-4729:8-2-021
- (n.d.). ORS 431A.855(1)(a)(B) and ORS 431A.860(1). oregonlegislature.gov. https://www.oregonlegislature.gov/bills_laws/ors/ors431a.html1
- (n.d.). Gabapentin will be a Schedule V controlled substance in Tennessee effective July 1, 2018. tn.gov. https://www.tn.gov/content/dam/tn/health/healthprofboards/New%20Statue%20Gabapentin%2006-18.pdf1
- (n.d.). Tenn. Code Ann. § 39-17-414(d)(3); Tenn. Comp. R. & Regs. 0940-06-01-.05. capitol.tn.gov. https://www.capitol.tn.gov/Bills/110/Bill/HB1832.pdf1
- (n.d.). 2024 Utah HB 260. le.utah.gov. https://le.utah.gov/~2024/bills/hbillhtm/HB0260.htm1
- (n.d.). Former Utah Code § 58-37-4. le.utah.gov. https://le.utah.gov/xcode/Title58/Chapter37/C58-37-S4_2024050120240501.html1
- (n.d.). Current Utah Code § 58-37-108. le.utah.gov. https://le.utah.gov/xcode/Title58/Chapter37/58-37-S108.html?v=C58-37-S108_20260506202605061
- (n.d.). Code of Virginia §54.1-3454 – Schedule V. Virginia General Assembly. https://law.lis.virginia.gov/vacode/title54.1/chapter34/section54.1-3454/1
- (n.d.). Va. Code Ann. § 54.1-3454; 2019 Va. Acts ch. 214 (HB 2557). lis.virginia.gov. https://lis.virginia.gov/cgi-bin/legp604.exe?191+ful+HB25571
- (n.d.). West Virginia Code §60A-2-212 – Schedule V Controlled Substances. West Virginia Legislature. https://code.wvlegislature.gov/60A-2-212/1
- (n.d.). W. Va. Code § 60A-2-212(f). code.wvlegislature.gov. https://code.wvlegislature.gov/60A-3-308/1
- (n.d.). Wis. Admin. Code CSB 4.03(2), 4.04(2), 4.05(1). docs.legis.wisconsin.gov. https://docs.legis.wisconsin.gov/document/administrativecode/CSB%204.03(2)1
- (n.d.). Wis. Admin. Code CSB 4.03(2), 4.04(2), 4.05(1). docs.legis.wisconsin.gov. https://docs.legis.wisconsin.gov/code/admin_code/csb/4/051
- (n.d.). Wyoming Administrative Rules, Board of Pharmacy, Chapter 8. rules.wyo.gov. https://rules.wyo.gov/Search.aspx?RefNum=%20059.0002.8.052420231
Further Reading
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the Gabapentin article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.